September 23, 2021 -- Everest Medicines and AbCellera have entered into a multiyear collaboration and license agreement to discover therapeutic antibodies for up to 10 targets that will be selected by Everest. The initial programs will focus on targets in oncology, Everest said.
Under the agreement, Everest will leverage AbCellera's technology, including sourcing fully humanized antibodies from the Trianni mouse, sourcing single-domain antibodies from camelids, and combining antibodies to create native bispecifics using the OrthoMab protein engineering platform.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
